EA200401301A1 - Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора - Google Patents
Полициклические соединения как эффективные антагонисты альфа-2 адренорецептораInfo
- Publication number
- EA200401301A1 EA200401301A1 EA200401301A EA200401301A EA200401301A1 EA 200401301 A1 EA200401301 A1 EA 200401301A1 EA 200401301 A EA200401301 A EA 200401301A EA 200401301 A EA200401301 A EA 200401301A EA 200401301 A1 EA200401301 A1 EA 200401301A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alpha
- adrenoreceptor
- polycyclic
- connections
- effective antagonists
- Prior art date
Links
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 title abstract 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940082496 Adrenoreceptor antagonist Drugs 0.000 abstract 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Secondary Cells (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Изобретение обеспечивает соединение формулы I, где X, Z, R-R, R, R, m, n, r и t являются такими, как определено в п.1, или его фармацевтически приемлемую соль или сложный эфир, применимые в качестве альфа-2 антагониста. Соединения формулы I могут быть использованы для лечения заболеваний или состояний, при которых показано, что антагонисты альфа-2 адренорецепторов являются эффективными.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36934702P | 2002-04-03 | 2002-04-03 | |
FI20020642A FI20020642A0 (fi) | 2002-04-03 | 2002-04-03 | Polysykliset yhdisteet tehokkaina alfa2-adrenoseptoriantagonisteina |
PCT/FI2003/000255 WO2003082866A1 (en) | 2002-04-03 | 2003-04-03 | Polycyclic compounds as potent alpha2-adrenoceptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200401301A1 true EA200401301A1 (ru) | 2005-06-30 |
EA008537B1 EA008537B1 (ru) | 2007-06-29 |
Family
ID=28676457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200401301A EA008537B1 (ru) | 2002-04-03 | 2003-04-03 | Полициклические соединения как эффективные антагонисты альфа2-адренорецептора |
Country Status (20)
Country | Link |
---|---|
US (1) | US7592350B2 (ru) |
EP (1) | EP1490361B1 (ru) |
JP (1) | JP2005522468A (ru) |
CN (1) | CN100372845C (ru) |
AT (1) | ATE374773T1 (ru) |
AU (1) | AU2003216760A1 (ru) |
BR (1) | BR0309028A (ru) |
CA (1) | CA2480695A1 (ru) |
DE (1) | DE60316672T2 (ru) |
EA (1) | EA008537B1 (ru) |
HK (1) | HK1075660A1 (ru) |
HR (1) | HRP20041026A2 (ru) |
HU (1) | HUP0500201A2 (ru) |
IL (1) | IL164203A0 (ru) |
IS (1) | IS7482A (ru) |
MX (1) | MXPA04009601A (ru) |
NZ (1) | NZ535950A (ru) |
PL (1) | PL372657A1 (ru) |
RS (1) | RS87204A (ru) |
WO (1) | WO2003082866A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI457122B (zh) | 2007-07-20 | 2014-10-21 | Orion Corp | 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3-二氫苯並[1,4]戴奧辛-2-基甲基衍生物 |
CA2716348C (en) | 2008-02-21 | 2017-04-04 | Sequoia Pharmaceuticals, Inc. | Diamide inhibitors of cytochrome p450 |
TW201024282A (en) | 2008-11-20 | 2010-07-01 | Orion Corp | New pharmaceutical compounds |
AU2010298168B2 (en) | 2009-09-23 | 2015-11-19 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
GB2503187A (en) * | 2011-09-15 | 2013-12-25 | Univ Sussex | Composition for use in the treatment of neurodevelopmental disorders |
TWI704145B (zh) | 2015-06-05 | 2020-09-11 | 芬蘭商奧利安公司 | 新醫藥化合物 |
CN107286158A (zh) * | 2016-03-30 | 2017-10-24 | 中国科学院上海药物研究所 | 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用 |
JP2019519582A (ja) | 2016-06-29 | 2019-07-11 | オリオン コーポレーション | ベンゾジオキサン誘導体およびその医薬用途 |
EP3773582B1 (en) | 2018-03-31 | 2023-10-25 | Molecular International Research, Inc. | Selective anti-cancer agent effective for prevention and treatment |
CN110922412A (zh) * | 2018-09-20 | 2020-03-27 | 复旦大学 | 具有抗精神病作用药物化合物的不对称合成方法 |
US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
TW202108135A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 治療睡眠呼吸中止症之α2-腎上腺素受體亞型C (α-2C)拮抗劑與TASK1/3通道阻斷劑之組合 |
TW202108136A (zh) | 2019-05-09 | 2021-03-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之α2-腎上腺素受體亞型C(α-2C)拮抗劑 |
CN111116578B (zh) * | 2019-12-26 | 2021-06-04 | 深圳市老年医学研究所 | 去亚甲基小檗碱的制备方法及其应用 |
BR112022026398A2 (pt) | 2020-07-06 | 2023-01-17 | Bayer Ag | Combinação de antagonista de receptor ¿2 adrenérgico subtipo c (alfa-2c) com bloqueador de canal task1/3 para tratamento da apneia do sono |
CN112457314A (zh) * | 2020-11-19 | 2021-03-09 | 烟台大学 | 手性吲哚并吲哚里西啶类化合物及其制备方法 |
WO2023118123A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an α2-adrenoceptor subtype c (alpha-2c) antagonist with a norepinephrine reuptake inhibitor for the treatment of sleep apnea |
AU2022422053A1 (en) | 2021-12-22 | 2024-07-11 | Bayer Aktiengesellschaft | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A MUSCARINIC RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA |
WO2023131638A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea |
WO2023131640A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1209650A (fr) | 1957-09-12 | 1960-03-02 | Hoffmann La Roche | Procédé pour la préparation de dérivés d'indolo-quinolizines |
GB844342A (en) | 1958-04-24 | 1960-08-10 | Roche Products Ltd | Novel quinolizine derivatives and a process for the manufacture thereof |
GB983848A (en) | 1960-03-12 | 1965-02-17 | Philips Nv | Improvements in or relating to indoloquinolizine compounds |
FR1524953A (fr) | 1962-03-26 | 1968-05-17 | Konink Pharmaceutische Fabrike | Procédé de préparation des dérivés de la quinolizine |
GB1003645A (en) | 1962-10-09 | 1965-09-08 | Koninklijke Pharma Fab Nv | Indolo-indolizine compounds |
US3203961A (en) * | 1963-03-21 | 1965-08-31 | Indolylethylpyrromdone compounds | |
US3492303A (en) * | 1967-07-28 | 1970-01-27 | Warner Lambert Pharmaceutical | 1,2,3,4,4a,5,6,8,9,14,14b,14c-dodecahydrobenz(h)indolo(2,3-a)quinolizines |
GB1435573A (en) | 1973-05-25 | 1976-05-12 | Wyeth John & Brother Ltd | Indoloquinolizines |
US4044012A (en) * | 1974-05-07 | 1977-08-23 | Richter Gedeon Vegyeszeti Gyar Rt. | Indolo-quinolizidine derivatives |
HU170495B (ru) * | 1974-05-07 | 1977-06-28 | ||
FR2478639A1 (fr) | 1980-03-20 | 1981-09-25 | Sanofi Sa | Nouveaux derives de l'indolizino (8,7-b) indole et intermediaires, leur procede de preparation et leur utilisation en therapeutique |
GB2106909B (en) | 1981-10-07 | 1984-09-19 | Wyeth John & Brother Ltd | Benzoquinolizines |
EP0089926A3 (de) | 1982-03-24 | 1984-05-16 | Ciba-Geigy Ag | Pharmazeutische Präparate enthaltend stickstoffhaltige Tetracyclen sowie neue Verbindungen dieser Art |
HU188022B (en) * | 1983-06-29 | 1986-03-28 | Richter Gedeon Vegyeszeti Gyar Rt,Hu | Process for production of derivatives of indolo /2,3-g/cyylopent /a/ indolizin |
GB2167408B (en) | 1984-11-23 | 1988-05-25 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
HU194221B (en) * | 1985-04-19 | 1988-01-28 | Richter Gedeon Vegyeszet | Process for preparing novel octahydro-indolo/2,3-a/quinoline derivative and pharmaceutical comprising this compound |
US4710504A (en) * | 1986-04-04 | 1987-12-01 | Merck & Co., Inc. | Anti-depressant spiro hexahydro arylquinolizine derivatives, composition, and method of use therefor |
NZ216283A (en) | 1985-06-03 | 1989-10-27 | Merck & Co Inc | Hexahydro arylquinolizine derivatives and pharmaceutical compositions |
AU582663B2 (en) * | 1985-08-10 | 1989-04-06 | John Wyeth & Brother Limited | Sulphonamides |
US4686226A (en) * | 1985-09-03 | 1987-08-11 | Merck & Co., Inc. | Substituted benzo[b]furo- and benzo[b]thieno quinolizines |
US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
RU2235092C2 (ru) | 1997-12-04 | 2004-08-27 | Оллерган Инк. | Замещенные производные имидазола, способ введения активного соединения и способ лечения на основе этих соединений |
FI20000480A0 (fi) | 2000-03-01 | 2000-03-01 | Orion Yhtymae Oyj | Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina |
-
2003
- 2003-04-03 EP EP03712185A patent/EP1490361B1/en not_active Expired - Lifetime
- 2003-04-03 DE DE60316672T patent/DE60316672T2/de not_active Expired - Lifetime
- 2003-04-03 MX MXPA04009601A patent/MXPA04009601A/es not_active Application Discontinuation
- 2003-04-03 AU AU2003216760A patent/AU2003216760A1/en not_active Abandoned
- 2003-04-03 CA CA002480695A patent/CA2480695A1/en not_active Abandoned
- 2003-04-03 RS YU87204A patent/RS87204A/sr unknown
- 2003-04-03 WO PCT/FI2003/000255 patent/WO2003082866A1/en active IP Right Grant
- 2003-04-03 IL IL16420303A patent/IL164203A0/xx unknown
- 2003-04-03 US US10/510,019 patent/US7592350B2/en not_active Expired - Fee Related
- 2003-04-03 CN CNB038084716A patent/CN100372845C/zh not_active Expired - Fee Related
- 2003-04-03 NZ NZ535950A patent/NZ535950A/en unknown
- 2003-04-03 JP JP2003580331A patent/JP2005522468A/ja active Pending
- 2003-04-03 AT AT03712185T patent/ATE374773T1/de not_active IP Right Cessation
- 2003-04-03 HU HU0500201A patent/HUP0500201A2/hu unknown
- 2003-04-03 EA EA200401301A patent/EA008537B1/ru not_active IP Right Cessation
- 2003-04-03 PL PL03372657A patent/PL372657A1/xx not_active Application Discontinuation
- 2003-04-03 BR BR0309028-0A patent/BR0309028A/pt not_active IP Right Cessation
-
2004
- 2004-10-01 IS IS7482A patent/IS7482A/is unknown
- 2004-11-02 HR HR20041026A patent/HRP20041026A2/xx not_active Application Discontinuation
-
2005
- 2005-09-05 HK HK05107766A patent/HK1075660A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ535950A (en) | 2007-11-30 |
US20070293527A9 (en) | 2007-12-20 |
CA2480695A1 (en) | 2003-10-09 |
EP1490361B1 (en) | 2007-10-03 |
HRP20041026A2 (en) | 2005-06-30 |
HUP0500201A2 (hu) | 2005-07-28 |
WO2003082866A1 (en) | 2003-10-09 |
AU2003216760A1 (en) | 2003-10-13 |
JP2005522468A (ja) | 2005-07-28 |
US20060094740A1 (en) | 2006-05-04 |
EA008537B1 (ru) | 2007-06-29 |
US7592350B2 (en) | 2009-09-22 |
PL372657A1 (en) | 2005-07-25 |
RS87204A (en) | 2006-10-27 |
BR0309028A (pt) | 2005-02-15 |
CN100372845C (zh) | 2008-03-05 |
IL164203A0 (en) | 2005-12-18 |
ATE374773T1 (de) | 2007-10-15 |
EP1490361A1 (en) | 2004-12-29 |
IS7482A (is) | 2004-10-01 |
DE60316672D1 (de) | 2007-11-15 |
CN1646528A (zh) | 2005-07-27 |
MXPA04009601A (es) | 2004-12-13 |
DE60316672T2 (de) | 2008-07-17 |
HK1075660A1 (en) | 2005-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200401301A1 (ru) | Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора | |
EA200300919A1 (ru) | N-замещенные неарильные гетероциклические антагонисты nmda/nr2b | |
EA200401309A1 (ru) | Тризамещённые гетероарилы и способы их получения и применения | |
RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
EA200500453A1 (ru) | Имидазопиридины и способы их получения и применения | |
EA200100971A1 (ru) | Новые соединения и композиции в качестве ингибиторов протеазы | |
EA200200619A1 (ru) | Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний | |
EA200400971A1 (ru) | Фторзамещенные циклоалканоиндолы, композиции, содержащие такие соединения, и способы лечения | |
EA200500508A1 (ru) | Диариловые эфиры в качестве антагониста опиоидного рецептора | |
EA200500814A1 (ru) | Производные пирролопиримидина | |
BG66085B1 (bg) | Фенилаланинови производни | |
EA200501274A1 (ru) | Пиразолы и способы их получения и применения | |
EA200400467A1 (ru) | Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора | |
EA200200873A1 (ru) | Новые пиперазиновые производные | |
EA200400953A1 (ru) | Замещённые пиридиноны в качестве модуляторов map-киназы p38 | |
EA200000804A1 (ru) | Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина | |
EA200300424A1 (ru) | Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов | |
HK1069339A1 (en) | Substituted diketopiperazines as oxytocin antagonists | |
BR0108816A (pt) | Derivados de quinolina como antagonistas alfa-2 | |
PA8561501A1 (es) | Lactamas como antagonistas de taquiquininas | |
EA200500803A1 (ru) | Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний | |
EA200201158A1 (ru) | Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов | |
EA200400806A1 (ru) | Способ получения эхинокандиновых соединений | |
EA200100618A1 (ru) | Антагонист витронектинового рецептора | |
EA200400588A1 (ru) | Линейные основные соединения, имеющие антагонистическую активность в отношении nk-2, и их композиции |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |